Lori Muffly, MD, is an associate professor of medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford Medicine.

Elias Jabbour, MD, is a professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Gregory Roloff, MD, is a hematologist/oncologist at the University of Chicago Medicine in Illinois

Overview of CAR T-cell Therapies in R/R B-cell ALL 

Video content above is prompted by the following:

Can you walk us through the currently available CAR T-cell Therapies for Relapsed / Refractory B-cell ALL, as well as some CAR T products currently being investigated?

Please comment on Brexucabtagene autoleucel (TECARTUS®), Tisagenlecleucel (KYMRIAH®), [Obecabtagene autoleucel (Obe-cel) ; Obe-Cel FDA Biologics License Application BLA News Release]

Videos

Evandro D. Bezerra, MD, provides an overview of current CAR T-cell therapies for relapsed/refractory B-cell acute lymphoblastic leukemia and explores emerging CAR T products under investigation. 

Lori Muffly, MD, associate professor of Medicine, Blood and Marrow Transplantation and Cellular therapy, Stanford Health Care, discusses the clinical outcomes with the use of a novel conditioning regimen featuring the anti-CD117 monoclonal antibody briquilimab (formerly JSP191) plus low-dose irradiation and fludarabine prior to allogeneic hemopoietic stem cell transplant (HSCT) in older patients with acute myeloid leukemia (AML).

In a subanalysis of a single-center phase 1 trial (NCT04429191), investigators examined this novel HSCT conditioning in a group of 12 patients 60 years of age or older with AML. Data presented at the 2023 Transplantation and Cellular Therapy Meetings showed that 9 patients had measurable residual disease (MRD) prior to HSCT, Muffly begins. At 1 year following HSCT, 6 of the 9 MRD-positive patients at baseline achieved MRD clearance, and the median time to MRD clearance was 90 days. Moreover, at 1 year, 67% of patients were alive and MRD negative, Muffly notes. The 1-year overall survival (OS) rate for all patients was 75%, and the 1-year relapse-free survival rate was 67%, Muffly says.

Investigators concluded that briquilimab plus low-dose irradiation and fludarabine demonstrated predictable clearance that allowed for safe and effective donor cell infusion between 9 and 14 days following briquilimab, Muffly concludes.

Lori Muffly, MD, discusses the clinical outcomes with the use of a novel conditioning regimen featuring the anti-CD117 monoclonal antibody briquilimab plus low-dose irradiation and fludarabine prior to allogeneic hemopoietic stem cell transplant in older patients with acute myeloid leukemia.

Lori Muffly, MD

Articles

Overview of CAR T-cell Therapies in R/R B-cell ALL

Dr. Muffly on the Evaluation of Briquilimab Conditioning Prior to HSCT in AML